Design, synthesis and biological evaluation of novel PARP inhibitors against acquired drug-resistance
- 20 December 2025
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 304, 118507
Abstract
No abstract availableKeywords
Funding Information
- Chinese Academy of Sciences (XDB0830000)
- National Natural Science Foundation of China (82073875)
This publication has 60 references indexed in Scilit:
- Novel ATR/PARP1 Dual Inhibitors Demonstrate Synergistic Antitumor Efficacy in Triple‐Negative Breast Cancer ModelsAdvanced Science, 2025
- Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathwayBiomedicine & Pharmacotherapy, 2025
- Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progressArchives of Pharmacal Research, 2024
- Pamiparib: First ApprovalDrugs, 2021
- Correction to: Fuzuloparib: First ApprovalDrugs, 2021
- Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancersInvestigational New Drugs, 2021
- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancerAnnals of Oncology, 2020
- Increased PARP1‐DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1‐DNA trapping is correlated with PARP1 inhibitor's cytotoxicityInternational Journal of Cancer, 2019
- Talazoparib: First Global ApprovalDrugs, 2018
- Niraparib: First Global ApprovalDrugs, 2017